Molecularly selected NSCLC patients with point mutation L858R or in-frame deletion of exon 19 (Ex19del) in EGFR (10–40% of NSCLC cases depending on the ethnicity of the population) are highly responsive to the first- and second-generation EGFR TKIs like gefitinib and apatinib [5, 6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.